New Therapeutics 09/22/2020 Releasing Peptides Growth Hormone Release

Somatostatin

Ipamorelin Sales Preferences LR3-IGF-1/CJC-1295/Ipamorelin: 600 mcg / 7.5 mg / 4.5 mg Daily dosing at 20 mcg / 250 mcg / 150 mcg

CJC-1295/Ipamorelin: improved ½ life >

Sermorelin/Ipamorelin: available in combo and single sterile vials and troches

MK-677: non-peptide, orally active, mimics GHRP LR3-IGF-1 LR3-IGF-1 Associated with reversing insulin sensitivity, reducing weight, and increasing metabolic expenditure. Modifications: • Retain the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor • Low affinity for the insulin-like growth factor-binding proteins (IGFBPs) • Improved metabolic stability • Approximately three times more potency than IGF-1 and possess a significantly longer half-life of about 20–30 hours (relative to IGF-1’s half-life of about 12–15 hours)

It differs from native IGF-1 in that it has an Arginine (R) instead of a Glutamic acid at the third (3) position in its amino acid sequence Has an additional 13 amino acids at its N-terminus (Long -L), for a total of 83 amino acids (compared to the 70 of IGF-1) Consisting of MFPAMPLLSLFVN (Met-Phe-Pro-Ala-Met-Pro-Leu-Leu-Ser-Leu-Phe-Val-Asn) LR3-IGF-1/CJC-1295/Ipamorelin LR3-IGF-1/CJC-1295/Ipamorelin • Fat mass significantly decreased in all groups, with the largest losses observed in GH and GH plus IGF-I groups (6.3 ± 1.8 and 8.4 ± 2.8 kg, respectively).

• Despite weight loss, BMR was maintained in all groups.

• Muscle strength increased with training for all groups

• Depression and anxiety scores decreased in groups receiving IGF-I

• These data show that obese postmenopausal women can lose weight and fat without compromising fat free mass, BMR, or gains in muscle strength, and that GH and IGF-I given together may enhance fat loss over either given alone.

• 12 weeks 12-24 lbs Selank and Semax Cognitive Peptides

Semax: Subq, Intranasal

Fragment of adrenocorticotropic hormone Serotonergic and Dopaminergic (ACTH)

Nootropic and Neuroprotective ADHD Benefits

Anxiolytic Stimulates Operative Memory & Attention

Immune Boosting Reduces Effects of Chronic Stress

Counteracts Inhibition of Learning and Promotes the Survival of Neurons During Memory From Heavy Metal Exposure Hypoxia (antihypoxic) Cognitive Peptides

Selank: Intranasal

Analog of Tuftsin -fragment of IgG Elevates Brain Derived Neurotrophic Factor (BDNF)

Anti-depressant Generalized Anxiety Disorder (GAD)

Anxiolytic - Non-sedating Boosts endogenous Enkephalins

T Immune Modulating - IL-6, h cells Reduces Effects of Chronic Stress Alcohol Withdrawal Symptoms -rodents Nootropic Cognitive Peptides

Dihexa: Oral 10 & 20 mg capsules, topical

Improves Cognitive Function in Animal 7X more potent than Brain Derived Models of Alzheimer's disease Neurotrophic Factor (BDNF)

Modulates Hepatocyte Growth Factor Reversal in animal models of damage to (HGF) -HGF found during brain recovery 60% of cerebral neurons

Induces Dendritic Arborization (Branching) Induces Dendritic Synaptogenesis

> 5 hr ½ life Crosses Blood Brain Barrier (BBB)

Anti Dementia Activity Parkinson's Disease Applications MOTS-c MOTS-c

• MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome

• MOTS-c targets muscle and regulates metabolism via the folate-purine-AMPK pathway

• MOTS-c mediates mitochondrial regulation of insulin and metabolic homeostasis

• MOTS-c protects against age- and diet-dependent insulin resistance and obesity MOTS-c MOTS-c

• MOTS-c targets muscle and regulates metabolism via the folate-purine-AMPK pathway

AMPK, short for monophosphate activated protein kinase, is an enzyme found in our cells that plays a critical role in energy metabolism. Think of it as a master switch turning on and off as it regulates energy intake and energy expenditure. MOTS-c GHKCu Topical and Injectables Hair Restoration

• GHK-Cu foam -benefits possible with dermaroller • Injectable shipped to patient, administered in office -microneedled into scalp • Increase in follicle size Kisspeptin Biochemistry Optimize Your Patients’ Health

Questions?

https://doi.org/10.1016/j.jgr.2018.07.007